SeekingAlpha · Nov 12, 2026
RadNet's Imaging Growth Can Fund DeepHealth's Hospital Rollout
RadNet (RDNT) stock's imaging and DeepHealth contracts support growth. ONRAD ties could add a DeepHealth sales channel at reasonable valuation. See more here.
NASDAQ · RDNT
Healthcare · Medical - Diagnostics & Research
$69.71
Up+$0.20 (+0.29%)
Updated Nov 22, 2026, 2:17 PM
SID Score
4.2/10
Composite research score
Smart Money
58/100
Neutral
Price performance · RDNT
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 20, 2026
RDNT closed at $69.71 after 20 trading sessions, down 0.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 20, 2026 | $68.28 | $70.855 | $68.00 | $69.71 | 594.24K |
| Nov 19, 2026 | $71.61 | $71.7575 | $68.55 | $69.51 | 748.34K |
| Nov 18, 2026 | $74.64 | $76.08 | $71.50 | $71.82 | 812.09K |
| Nov 17, 2026 | $76.24 | $76.59 | $74.77 | $74.92 | 393.62K |
| Nov 16, 2026 | $77.00 | $77.00 | $75.495 | $76.89 | 565.02K |
| Nov 13, 2026 | $76.49 | $76.98 | $75.06 | $76.42 | 476.31K |
| Nov 12, 2026 | $78.09 | $78.25 | $75.91 | $76.04 | 408.02K |
| Nov 11, 2026 | $79.03 | $79.96 | $77.83 | $78.08 | 732.34K |
| Nov 10, 2026 | $80.86 | $80.9999 | $77.16 | $77.94 | 661.49K |
| Nov 9, 2026 | $75.58 | $80.70 | $73.22 | $78.38 | 1.26M |
| Nov 6, 2026 | $77.21 | $78.13 | $72.485 | $76.00 | 1.66M |
| Nov 5, 2026 | $81.00 | $81.87 | $77.74 | $78.01 | 1.05M |
| Nov 4, 2026 | $75.32 | $80.57 | $74.35 | $80.26 | 1.73M |
| Nov 3, 2026 | $73.98 | $74.78 | $72.84 | $73.18 | 988.53K |
| Nov 2, 2026 | $73.90 | $75.17 | $73.03 | $73.10 | 960.74K |
| Oct 30, 2026 | $73.56 | $74.39 | $71.91 | $73.49 | 571.7K |
| Oct 29, 2026 | $74.49 | $75.05 | $73.40 | $73.65 | 472.1K |
| Oct 28, 2026 | $73.48 | $75.02 | $73.33 | $73.54 | 633.16K |
| Oct 27, 2026 | $70.53 | $74.56 | $70.49 | $73.54 | 1.27M |
| Oct 26, 2026 | $70.58 | $71.77 | $69.76 | $70.05 | 340.09K |
The latest Smart Investors Daily articles mentioning RDNT.
Company
Market Activity
Research & News
RDNT research
Company profile and research snapshot.
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 10, 2026 | Keybanc | Overweight | — |
| Aug 28, 2026 | Barclays | Overweight | — |
| Aug 11, 2026 | Truist Securities | Buy | — |
| May 20, 2026 | Barclays | Overweight | — |
| Apr 21, 2026 | Barclays | Overweight | — |
No generated briefing is available yet.
SeekingAlpha · Nov 12, 2026
RadNet (RDNT) stock's imaging and DeepHealth contracts support growth. ONRAD ties could add a DeepHealth sales channel at reasonable valuation. See more here.
Yahoo · Nov 11, 2026
RadNet (RDNT) just signaled a more acquisition focused phase after its Q3 2026 update, with management highlighting a sizable cash position and plans to pursue tuck in deals across its operating segments. Recent trading reflects that shift in tone. RadNet’s share price return is up 9.9% over the past month and 9.9% year to date, while the 1 year total shareholder return is slightly down 0.7%. This is set against a very large 3 year total shareholder return of about 15x that hints at earlier...
Yahoo · Nov 11, 2026
RadNet reported record third quarter 2026 results, with revenue of US$638.26 million, strong adjusted EBITDA, and raised full year guidance supported by advanced imaging, digital health, and new center and joint venture contributions. Management highlighted a cash balance of US$750.6 million, modest net leverage of 1.66x adjusted EBITDA, and active plans for tuck in acquisitions and efficiency focused deals such as ONRAD and other underperforming operators. We now examine how RadNet’s record...
Yahoo · Nov 10, 2026
Diagnostic imaging company RadNet (NASDAQ:RDNT) will be reporting earnings this Monday before market open. Here’s what you need to know.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning RDNT.